

In response to the restriction requirement, Applicant provisionally elects to prosecute the invention of Group I (Claims 1 – 10), drawn to methods of treating a patient with an ophthalmic disease caused by a mutation in the gene GLC1A utilizing an aminoglycoside antibiotic compound. Applicant makes this election with traverse. Both the GLC1A and CYP1B1 genes are glaucoma genes. The aminoglycoside antibiotics used to treat the diseases caused by either gene are the same antibiotics. The claimed method involves the same step: administering an aminoglycoside antibiotic. And the claimed method has the same goal: treating the disease by overcoming the stop mutation and allowing sufficient amounts of functional protein to be expressed. Applicant requests that the Examiner withdraw the restriction requirement.

Applicants believe that the above remarks have placed Claims 1 – 10 in condition for allowance. Accordingly, allowance of the claims in this application is respectfully requested.

Respectfully submitted,

ALCON

January 10, 2006
Date

Patrick M. Ryan
Patrick M. Ryan
Reg. No. 36,263

Address for Correspondence:
Alcon Research, Ltd.
R&D Counsel Q-148
6201 South Freeway
Fort Worth, TX 76134-2099
(817) 551-3066
Docket: 1910